LivaNova (NASDAQ:LIVN) Releases Quarterly Earnings Results, Beats Expectations By $0.17 EPS

LivaNova (NASDAQ:LIVN) issued its earnings results on Wednesday. The company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17, FiscalAI reports. The business had revenue of $393.15 million during the quarter, compared to analysts’ expectations of $381.13 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. LivaNova’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.11 EPS.

Here are the key takeaways from LivaNova’s conference call:

• Broad-based growth led to higher guidance. Third-quarter revenue rose 10% to $393 million, and LivaNova raised its 2026 revenue growth outlook to 9%–10% and adjusted EPS outlook to $4.40–$4.50.
• Cardiopulmonary growth and capacity expansion are supporting further gains. Segment revenue increased 11%, with strength in heart-lung machines and consumables; a new oxygenator line is operational, and the company expects double-digit output growth in 2027.
• Epilepsy momentum strengthened. Revenue grew 11%, supported by higher volume and realized pricing, clinical evidence, and improved reimbursement; LivaNova raised its 2026 epilepsy growth outlook to 8%–9%.
• OSA remains a key future growth opportunity, though commercialization is still ahead. The company cited differentiated clinical results and new category CPT codes expected to take effect in 2028, while planning a limited launch in 2027 and larger commercial investment beginning in 2028.
• Investment and working-capital needs weighed on cash generation. Quarterly adjusted free cash flow fell to $56 million from $62 million a year earlier, while capital spending increased; full-year adjusted free cash flow guidance was maintained at $140 million–$160 million.

LivaNova Stock Performance

LIVN stock traded up $15.24 during mid-day trading on Wednesday, hitting $95.14. 2,728,848 shares of the company were exchanged, compared to its average volume of 739,353. The stock has a market capitalization of $5.24 billion, a PE ratio of 28.15 and a beta of 0.91. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. LivaNova has a 1-year low of $48.82 and a 1-year high of $99.38. The business has a 50 day simple moving average of $78.56 and a 200-day simple moving average of $73.10.

Insider Activity

In other LivaNova news, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the sale, the director owned 7,488 shares in the company, valued at $609,672.96. The trade was a 23.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the completion of the sale, the director owned 4,434 shares of the company’s stock, valued at approximately $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 7,450 shares of company stock worth $591,839 over the last 90 days. 0.35% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on LIVN shares. Weiss Ratings upgraded shares of LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, October 27th. Barclays upgraded LivaNova to a “strong-buy” rating in a research report on Wednesday, October 7th. Zacks Research cut shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Needham & Company LLC lifted their price target on shares of LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Mizuho lifted their target price on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $90.12.

Trending Headlines about LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Quarterly results beat expectations: LivaNova reported adjusted earnings of $1.23 per share, above estimates of $1.03–$1.06 and up from $1.11 a year earlier. Revenue rose 9.9% year over year to $393.1 million, exceeding analyst forecasts of about $381 million. LivaNova Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Full-year outlook improved: The company raised its full-year EPS guidance, signaling increased confidence in its earnings outlook. LivaNova Beats Q3 Estimates and Raises Full-Year EPS Guidance
• Positive Sentiment: Analyst sees more upside: Needham raised its price target to $112 from $93 and maintained a Buy rating, reflecting a more favorable view of the shares. Needham & Company recommendations

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.